| 16 Octobre 2022
NEWTOWN SQUARE, Pa., Sept. 30, 2022 /PRNewswire/ -- Kibow Biotech, Inc., a clinical-stage biotechnology company developing live biotherapeutics that target the dysbiosis in patients with CKD, today celebrated a 25-year legacy of dedication to improving the lives of patients with kidney disease.
"We are evolving into a leading microbiome-focused biotechnology company, building on our foundation of 25 years researching and developing solutions to help kidney disease patients," said Natarajan Ranganathan, PhD., Founder and Chairman of Kibow. "Since pioneering the concept of "Enteric DialysisÒ," we have launched RENADYLÔ as a dietary supplement to maintain kidney health. We are now studying US-APR2020 in clinical trials to prepare for a future BLA submission as potentially the first live biotherapeutic product (LBP) to improve outcomes in patients with CKD."
Kibow has dedicated 25 years of research and development to modulating the gut microbiome with a primary focus on chronic kidney disease (CKD). The clinical trials currently underway are seeking to demonstrate the safety and efficacy of our encapsulated blend of proprietary strains of commensal bacteria targeting uremic toxins associated with CKD.
Kibow is also excited to announce its 17th consecutive year of participation at the American Society of Nephrology's ASN Kidney Week Conference, November 3-6, 2022, in Orlando, Florida. We will be exhibiting and providing updates about our ongoing clinical trials for the LBP candidate, US-APR2020.
Contact Info:
Graham G. Lumsden, CEO
610-353-5130
Email:
Cette adresse email est protégée contre les robots des spammeurs, vous devez activer Javascript pour la voir.
About Kibow: Founded in Philadelphia in October 1997, Kibow specializes in the research, development, and commercialization of live biotherapeutics and probiotic dietary supplements. The Company's flagship product, RENADYL™, is marketed in the US and several other countries as a dietary supplement to maintain kidney health. Kibow's focus on Enteric Dialysis® modulates the intestinal microbiome with highly specific strains of commensal bacteria and selected functional fibers to overcome the dysbiosis associated with CKD. The name Kibow, which means "hope" in Japanese, is derived from the vision of improving failingÂÂ Kidney function by restoring the microbiome in theÂÂ BOWel. Additional information can be found at www.kibowbiotech.com.
About CKD: Kidney disease affects an estimated 850 million people worldwide, and few available treatments are approved to treat the disease. Most often linked to comorbidities such as diabetes and hypertension, if untreated, patients face the option of dialysis or renal transplant. Kidney disease represents one of the largest costs to healthcare systems around the world. In the U.S., the estimated cost in 2021 was more than $130 billion, according to the United States Renal Data System 2021 Annual Report.
